Daraxonrasib is a once-daily oral targeted therapy developed by Revolution Medicines for cancers driven by RAS mutations.
Rasonque Tradename
It is a ( “RAS(ON)” inhibitor that works by blocking mutated RAS proteins (such as KRAS) across multiple variants, which historically were considered undruggable.
An oral multiselective, tricomplex inhibitor of the active guanosine triphosphate-bound state of mutant and wild type RAS.
The drug has shown unprecedented results, notably doubling median overall survival to approximately 13.2 months compared to 6.7 months with standard chemotherapy in patients with previously treated metastatic pancreatic cancer.
Among patients with previously treated metastatic pancreatic and no carcinoma, treatment with direct directive led to significantly longer overall survival and progression free survival than chemotherapy.
While most targeted therapies only work for specific gene variants, daraxonrasib works as a multiselective inhibitor that turns off various overactive KRAS proteins to stop tumor growth.
Side Effects: While not completely devoid of side effects, it is considered much more tolerable than standard cytotoxic chemotherapy, allowing for better quality of life.
Common side effects include rash, diarrhea, nausea, and mouth sores.
Other Cancers: In addition to pancreatic ductal adenocarcinoma (PDAC), clinical trials are actively studying its efficacy in treating other RAS-mutated solid tumors, such as non-small cell lung cancer (NSCLC) and colorectal cancer.
Among patients with previously treated metastatic RAS mutant NSCLC receiving daraxonrasib at a dose of 300 mg or less daily, 54% at adverse events of grade 3 or higher, and anti-tumor activity was reported in more than 30%.
Adverse events of grade 3 or higher reported in 54% of patients with pneumonia (10%), diarrhea (9%), rash (8%), and anemia (5%) occurring in at least 5% of patients,4 grade 5 adverse events occurred.